Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial

Sergio H.R. Ramalho; Brian L. Claggett; Nancy K. Sweitzer; James C. Fang; Sanjiv J. Shah; Inder S. Anand; Bertram Pitt; Eldrin F. Lewis; Marc A. Pfeffer; Scott D. Solomon; Amil M. Shah

doi:10.1002/ejhf.1593

Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial

Sergio H.R. Ramalho, Brian L. Claggett, Nancy K. Sweitzer, James C. Fang, Sanjiv J. Shah, Inder S. Anand, Bertram Pitt, Eldrin F. Lewis, Marc A. Pfeffer, Scott D. Solomon, Amil M. Shah^*

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	557-559
Number of pages	3
Journal	European Journal of Heart Failure
Volume	22
Issue number	3
DOIs	https://doi.org/10.1002/ejhf.1593
State	Published - Mar 1 2020

Funding

TOPCAT was funded by National Heart, Lung, and Blood Institute, National Institutes of Health (Bethesda, MD), Contract Number HHSN268200425207C. The content of this paper does not necessarily represent the views of the sponsor or of the Department of Health and Human Services. The work for this manuscript was also supported by NIH/NHLBI grants K08HL116792, R01HL135008, and R01HL143224 (Dr. Shah), and a Watkins Discovery Award from the Brigham and Women's Heart and Vascular Center (Dr. Shah). Conflict of interest: A.M.S. has received research support from Novartis and consulting fees from Philips Ultrasound and Bellerophon. All other authors have nothing to disclose. TOPCAT was funded by National Heart, Lung, and Blood Institute, National Institutes of Health (Bethesda, MD), Contract Number HHSN268200425207C. The content of this paper does not necessarily represent the views of the sponsor or of the Department of Health and Human Services. The work for this manuscript was also supported by NIH/NHLBI grants K08HL116792, R01HL135008, and R01HL143224 (Dr. Shah), and a Watkins Discovery Award from the Brigham and Women's Heart and Vascular Center (Dr. Shah). Conflict of interest: A.M.S. has received research support from Novartis and consulting fees from Philips Ultrasound and Bellerophon. All other authors have nothing to disclose. The authors wish to thank the staff and participants of the TOPCAT study for their important contributions. TOPCAT was funded by National Heart, Lung, and Blood Institute, National Institutes of Health (Bethesda, MD), Contract Number HHSN268200425207C. The content of this paper does not necessarily represent the views of the sponsor or of the Department of Health and Human Services. The work for this manuscript was also supported by NIH/NHLBI grants K08HL116792, R01HL135008, and R01HL143224 (Dr. Shah), and a Watkins Discovery Award from the Brigham and Women's Heart and Vascular Center (Dr. Shah). Conflict of interest: A.M.S. has received research support from Novartis and consulting fees from Philips Ultrasound and Bellerophon. All other authors have nothing to disclose.

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1002/ejhf.1593

Cite this

@article{6ed8ae5d08554ae2b8f74fc78fa7f593,

title = "Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial",

author = "Ramalho, {Sergio H.R.} and Claggett, {Brian L.} and Sweitzer, {Nancy K.} and Fang, {James C.} and Shah, {Sanjiv J.} and Anand, {Inder S.} and Bertram Pitt and Lewis, {Eldrin F.} and Pfeffer, {Marc A.} and Solomon, {Scott D.} and Shah, {Amil M.}",

note = "Funding Information: TOPCAT was funded by National Heart, Lung, and Blood Institute, National Institutes of Health (Bethesda, MD), Contract Number HHSN268200425207C. The content of this paper does not necessarily represent the views of the sponsor or of the Department of Health and Human Services. The work for this manuscript was also supported by NIH/NHLBI grants K08HL116792, R01HL135008, and R01HL143224 (Dr. Shah), and a Watkins Discovery Award from the Brigham and Women's Heart and Vascular Center (Dr. Shah). Conflict of interest: A.M.S. has received research support from Novartis and consulting fees from Philips Ultrasound and Bellerophon. All other authors have nothing to disclose. Funding Information: TOPCAT was funded by National Heart, Lung, and Blood Institute, National Institutes of Health (Bethesda, MD), Contract Number HHSN268200425207C. The content of this paper does not necessarily represent the views of the sponsor or of the Department of Health and Human Services. The work for this manuscript was also supported by NIH/NHLBI grants K08HL116792, R01HL135008, and R01HL143224 (Dr. Shah), and a Watkins Discovery Award from the Brigham and Women's Heart and Vascular Center (Dr. Shah). Conflict of interest: A.M.S. has received research support from Novartis and consulting fees from Philips Ultrasound and Bellerophon. All other authors have nothing to disclose. The authors wish to thank the staff and participants of the TOPCAT study for their important contributions. TOPCAT was funded by National Heart, Lung, and Blood Institute, National Institutes of Health (Bethesda, MD), Contract Number HHSN268200425207C. The content of this paper does not necessarily represent the views of the sponsor or of the Department of Health and Human Services. The work for this manuscript was also supported by NIH/NHLBI grants K08HL116792, R01HL135008, and R01HL143224 (Dr. Shah), and a Watkins Discovery Award from the Brigham and Women's Heart and Vascular Center (Dr. Shah). Conflict of interest: A.M.S. has received research support from Novartis and consulting fees from Philips Ultrasound and Bellerophon. All other authors have nothing to disclose.",

year = "2020",

month = mar,

day = "1",

doi = "10.1002/ejhf.1593",

language = "English (US)",

volume = "22",

pages = "557--559",

journal = "European Journal of Heart Failure",

issn = "1388-9842",

publisher = "John Wiley and Sons Ltd",

number = "3",

}

TY - JOUR

T1 - Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction

T2 - the TOPCAT trial

AU - Ramalho, Sergio H.R.

AU - Claggett, Brian L.

AU - Sweitzer, Nancy K.

AU - Fang, James C.

AU - Shah, Sanjiv J.

AU - Anand, Inder S.

AU - Pitt, Bertram

AU - Lewis, Eldrin F.

AU - Pfeffer, Marc A.

AU - Solomon, Scott D.

AU - Shah, Amil M.

N1 - Funding Information: TOPCAT was funded by National Heart, Lung, and Blood Institute, National Institutes of Health (Bethesda, MD), Contract Number HHSN268200425207C. The content of this paper does not necessarily represent the views of the sponsor or of the Department of Health and Human Services. The work for this manuscript was also supported by NIH/NHLBI grants K08HL116792, R01HL135008, and R01HL143224 (Dr. Shah), and a Watkins Discovery Award from the Brigham and Women's Heart and Vascular Center (Dr. Shah). Conflict of interest: A.M.S. has received research support from Novartis and consulting fees from Philips Ultrasound and Bellerophon. All other authors have nothing to disclose. Funding Information: TOPCAT was funded by National Heart, Lung, and Blood Institute, National Institutes of Health (Bethesda, MD), Contract Number HHSN268200425207C. The content of this paper does not necessarily represent the views of the sponsor or of the Department of Health and Human Services. The work for this manuscript was also supported by NIH/NHLBI grants K08HL116792, R01HL135008, and R01HL143224 (Dr. Shah), and a Watkins Discovery Award from the Brigham and Women's Heart and Vascular Center (Dr. Shah). Conflict of interest: A.M.S. has received research support from Novartis and consulting fees from Philips Ultrasound and Bellerophon. All other authors have nothing to disclose. The authors wish to thank the staff and participants of the TOPCAT study for their important contributions. TOPCAT was funded by National Heart, Lung, and Blood Institute, National Institutes of Health (Bethesda, MD), Contract Number HHSN268200425207C. The content of this paper does not necessarily represent the views of the sponsor or of the Department of Health and Human Services. The work for this manuscript was also supported by NIH/NHLBI grants K08HL116792, R01HL135008, and R01HL143224 (Dr. Shah), and a Watkins Discovery Award from the Brigham and Women's Heart and Vascular Center (Dr. Shah). Conflict of interest: A.M.S. has received research support from Novartis and consulting fees from Philips Ultrasound and Bellerophon. All other authors have nothing to disclose.

PY - 2020/3/1

Y1 - 2020/3/1

UR - http://www.scopus.com/inward/record.url?scp=85074835452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074835452&partnerID=8YFLogxK

U2 - 10.1002/ejhf.1593

DO - 10.1002/ejhf.1593

M3 - Letter

C2 - 31667977

AN - SCOPUS:85074835452

SN - 1388-9842

VL - 22

SP - 557

EP - 559

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

IS - 3

ER -

Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this